Clinical trials: Rhinitis Seasonal
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis(SAR)and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00377728
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb/III study encompassing a phase IIb and a phase III component.
- Trial name
- Pumecitinib (NCT06837233)
- Testing
- Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Pumecitinib nasal spray 0.6%(twice daily)
- Where
- 20 sites in China
- Volunteers
- 179 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Seasonal Allergic Rhinitis
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.
- Trial name
- NCT00491504
- Testing
- Mometasone Furoate Nasal Spray
- Volunteers
- 310 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Seasonal
Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)
This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.
- Trial name
- NCT03861559
- Testing
- mometasone furoate nasal spray
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis
The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.
- Trial name
- NCT05098522
- Testing
- IRL201104
- Where
- 2 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Revolo Biotherapeutics
Allergic Rhinitis
Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.
- Trial name
- NCT00638118
- Testing
- Fexofenadine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sanofi